Cardiometabolic risk factors in T2DM improved by rimonabant

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1655, 2008-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study

By Florentin M   Liberopoulos EN   Filippatos TD   Kostara C   Tselepis A   Mikhailidis DP   Elisaf M  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 16, 2008-11 ,pp. : 2741-2750

Informa Healthcare

Access to resources Recommend Favorite

Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors

By Gelfand Eli V   Cannon Christopher P  

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 3, 2006-03 ,pp. : 307-315

Informa Healthcare

Access to resources Recommend Favorite

Rimonabant reduces risk factors for cardiovascular disease

By  

Inpharma, Vol. 1, Iss. 1429, 2004-01 ,pp. : 7-9

Adis International

Access to resources Recommend Favorite

Rimonabant improves multiple risk factors in RIO-DIABETES

By  

Inpharma, Vol. 1, Iss. 1498, 2005-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

A fixed combination of rosiglitazone plus metformin improves glycaemic control and cardiovascular risk factors in patients with type 2 diabetes mellitus (T2DM)

By  

Inpharma, Vol. 1, Iss. 1546, 2006-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite